- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, explains reimbursement challenges that community settings face with access to multigene testing.
Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, explains reimbursement challenges that community settings face with access to multigene testing.
Transcript
From a reimbursement standpoint, are there challenges with providing access to multigene testing in the community setting?
One of the problems with genetic testing is that many of the insurers have very rigorous policies about how they’ll allow testing, and that’s really restricted testing. In some cases even, large insurers have demanded that a genetic counselor do a consult. My own practice has been very fortunate to have genetic counselors for over 20 years, and they are wonderful, but they can be overwhelmed with the amount of patients. So, if we’re going to expand the criteria, then we have to have the insurance say we’re going to pay for this and we also have to have new delivery models of how people get tested and how they’re explained what the results of those testing are. One of the things about genetic testing that’s different than traditional taking care of patients is you’re not just talking about the person whose being tested because it has implications for the family. And so, you have to think more broadly of how are we going to get more people in to test, what is their decision making, how do we inform them on it, and there are issues there of expanded insurance.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Ways Providers, Payers Can Ensure Biomarker Testing Is Done in Cancer Care
October 18th 2024There is a role for both payers and providers to make small changes that would increase the use of biomarker testing to ensure patients are receiving the appropriate treatment, said Susan Wescott, RPh, MBA, senior director of managed care pharmacy, Mayo Clinic.
Read More
